Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition

Checkpoint inhibitors have revolutionized cancer therapy and validated immunotherapy as an approach. Unfortunately, responses are seen in a minority of patients. Our objective is to use engineered adenoviruses designed to increase lymphocyte trafficking and cytokine production at the tumor, to asses...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Victor Cervera-Carrascon, Dafne C.A. Quixabeira, Joao Manuel Santos, Riikka Havunen, Sadia Zafar, Otto Hemminki, Camilla Heiniö, Eleonora Munaro, Mikko Siurala, Suvi Sorsa, Tuomas Mirtti, Petrus Järvinen, Markus Mildh, Harry Nisen, Antti Rannikko, Marjukka Anttila, Anna Kanerva, Akseli Hemminki
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Taylor & Francis Group 2020-01-01
Edice:	OncoImmunology
Témata:	oncolytic virus adenovirus checkpoint inhibitors immunotherapy tumor microenvironment
On-line přístup:	http://dx.doi.org/10.1080/2162402X.2020.1761229
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!